🔗 Share this article

Chancellor Reeves has revealed she is planning "specific measures to tackle cost of living challenges" in the forthcoming Budget.

Speaking to the BBC, she noted that lowering price rises is a joint duty of both the administration and the Bank of England.

The UK's price growth is forecast to be the highest among the Group of Seven advanced economies this calendar year and the following year.

Potential Utility Bill Interventions

It is understood the administration could take action to lower utility costs, for instance by cutting the current 5% rate of value-added tax applied on energy supplies.

A further possibility is to reduce some of the government charges currently added to bills.

Budgetary Constraints and Expert Predictions

The government will receive the next draft from the official forecaster, the OBR, on the start of the week, which will clarify how much scope there is for these actions.

The consensus from most economists is that the Chancellor will have to introduce higher taxes or spending cuts in order to meet her self-imposed borrowing rules.

Earlier on Thursday, analysis suggested there was a twenty-two billion pound gap for the chancellor to fill, which is at the more modest range of expectations.

"It is a joint job between the Bank of England and the administration to continue tackling some of the sources of inflation," the Chancellor stated to the BBC in Washington, at the yearly gatherings of the IMF and global financial institution.

Revenue Pledges and Global Issues

While a great deal of the focus has been on likely tax rises, the chancellor said the most recent data from the OBR had not changed her vow to election pledges not to increase rates on earnings tax, VAT or National Insurance.

She blamed an "uncertain global environment" with rising international and trade concerns for the fiscal tax moves, likely to be targeted on those "wealthiest."

Global Trade Disputes

Addressing apprehensions about the United Kingdom's commercial links with the Asian nation she said: "The UK's security interests always are paramount."

Recent announcement by Chinese authorities to increase trade restrictions on rare earths and other resources that are key for advanced tech manufacturing led American leader Donald Trump to suggest an further 100% tariff on goods from China, increasing the prospect of an full-scale trade war between the two economic giants.

The American finance chief called the Chinese decision "commercial pressure" and "a international production control attempt."

Asked about accepting the American proposal to join its dispute with the Asian nation, the Chancellor said she was "very concerned" by China's actions and urged the Chinese government "not to put up barriers and limit trade."

She said the action was "bad for the global economy and generates additional obstacles."

"I believe there are sectors where we should challenge Chinese policies, but there are also valuable chances to trade with Chinese markets, including banking sector and other areas of the economic system. We've got to maintain that equilibrium right."

The Treasury chief also stated she was collaborating with G7 counterparts "regarding our own critical minerals approach, so that we are reduced dependence."

NHS Medicine Pricing and Investment

The Chancellor also acknowledged that the cost the NHS spends on pharmaceuticals could go up as a result of current negotiations with the Trump administration and its pharmaceutical firms, in return for reduced taxes and capital.

A number of the world's largest pharmaceutical manufacturers have said in recent statements that they are either delaying or scrapping projects in the United Kingdom, with some blaming the insufficient payments they are getting.

Recently, the government science advisor said the cost the health service spends on medicines would have to increase to prevent businesses and pharmaceutical investment departing from the UK.

The Chancellor stated to media: "It has been observed due to the pricing regime, that medical research, recent pharmaceuticals have not been offered in the United Kingdom in the extent that they are in other European countries."

"The objective is to make sure that people receiving care from the NHS are can receive the best essential treatments in the world. And so we are reviewing all of that, and... seeking to obtain more investment into Britain."